Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 72 Face-to-Face Consultations Provided from July 2011 through September 2013: PMDA
October 21, 2013
- Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
- CSIMC’s Bill Payer, Industry Reps at Odds over Objective of Premium; “Elimination of Drug Lag” vs. “New Drug Development”
October 18, 2013
- 1st Committee on Drugs to Discuss Approval for JT’s Hyperphosphatemia Treatment on October 28
October 18, 2013
- 60% of Products/Indications in 1st Round of Development Requests Approved as of June: MHLW
October 18, 2013
- CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation
October 17, 2013
- CSIMC to Study Introduction of Medical Fee for DPC Hospitals with High Generic Drug Use Rates in Fee-for-Service System
October 17, 2013
- PMDA to Kick Off Pilot Program for Electronic Filings of NDA Data in October
October 16, 2013
- Japan “Hopes to Find Common Ground” in Upcoming TPP Talks on Intellectual Properties: Minister Amari
October 16, 2013
- Generic-Name Prescribing Promoted Use of Generic Drugs in FY2012: CSIMC Committee
October 11, 2013
- CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar
October 10, 2013
- Expert Group Calls for Handling of Switch OTC Drugs as Careful as Ethical Drugs in Early Stage after Switching
October 10, 2013
- Working Group Finalizes Recommendation on Rules for Online Sales of OTC Drugs
October 10, 2013
- MHLW Formally Compiles Interim Report of Expert Panel on Diovan Scandal
October 10, 2013
- Applications Based on Information in Public Domain Appropriate for 4 Drugs Including Vancomycin: Council on Unapproved Drugs
October 9, 2013
- Nonpartisan Lawmaker Group to Hold Study Session on Diovan Scandal
October 8, 2013
- Council on Regulatory Reform to Begin Holding Open Public Discussions Later This Year
October 8, 2013
- Addition of TACE Use for Farmorubicin to Be Reported to PAFSC Second Committee
October 7, 2013
- NIBIO to Strengthen Academia’s Drug Discovery Support Initiatives in Order to Evaluate 400 Research Themes by FY2015
October 4, 2013
- PMDA Considers Offering Development Strategy Consultations to Drug Makers: Office Director
October 3, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…